News Release

EPS Group Form Strategic Reorganization for CRO Business
TOKYO, Japan, 4th July 2022 – EPS International Holdings Co., Ltd. (“EPS International”, hereafter) andEPS Corporation (“EPS”, hereafter), both of which are wholly owned subsidiaries of EPS Holdings, Inc.,
announced that EPS International and EPS have decided to merge through an absorption-type merger, with EPS
as the surviving company and EPS International as the absorbed company on 1st September 2022.
１．Purpose of the Reorganization
Last year, the EPS Group celebrated its 30th anniversary and conducted a management buyout (MBO), moving
toward "The New EPS". The reorganization of the domestic CRO business was completed on schedule as of 1st
July 2022, and this reorganization is related to the overseas business following the domestic business.
EPS International has been expanding its services to overseas clients, especially inbound projects from Europe,
the U.S., and China, focusing not only on functional services, in which some development functions areoutsourced in Japan, but also on full services requiring an in-country clinical trial manager. Recently, however,the business environment surrounding CROs has been undergoing significant changes.
As years go by, Multi-National Clinical Trials are becoming the mainstream of clinical trials, and the use ofreal-world data, including patient registry data, is being expanded. Cross-border data sharing is expected to befurther accelerated in the future as globalization progresses and the barriers between clinical trials and the realworld are becoming lower.
The purpose of this reorganization is to provide solutions that meet the needs of a New Era in both domestic
and overseas operations by integrating the experience, project management and know-how of EPS, a leading
company in the CRO industry that provides drug development support services in Japan, and EPS International,
which focuses on full-service drug development support for overseas clients.
The EPS Group will contribute to the further progress of the health industry by providing high-quality services
as a good partner to its customers, as well as strengthening the local medical system and improving people'shealth.
２．Scheduled Merging Effective Date
1st September 2022

３．Overview of Reorganization
Surviving company

Absorbed company

Name

EPS Corporation

EPS International Holdings Co., Ltd.

Address

2-23 Shimomiyabicho, Shinjuku-ku,

1-8 Tsukudocho, Shinjuku-ku, Tokyo,Tokyo, 162-0822, Japan

162-0821, Japan

Akira Sasa

Tomohisa Hayakawa

CRO business, Post-marketing

CRO business mainly for overseer’s

surveillance and Pharmacovigilanceclients, In-Country Clinical CaretakerSupport(ICCC) in Japan# of Employees*

3,187

228

CapitalJPY 100,000,000

JPY 100,000,000

Stockholder

EPS Holdings, Inc. (100%)

EPS Holdings, Inc. (100%)

Representative
DirectorBusiness

As of 1st July 2022

[About EPS International and EPS group]
Since its establishment in 1991 as one of pioneering CROs, EPS Group has been a Healthcare Solution
Provider to pharmaceutical companies, medical device manufacturers, hospitals and clinics, and academia
with various solutions from development to marketing, sales, consultation covering Asia centered in Chinaand new values created in big data & AI, regenerative medicine, etc. The strength of EPS Internationallies in the fact that it has the greatest presence in Japan. In Asia, the company has multiple overseas
offices and has focused particularly on solidifying its sites in the respective Asian countries, providing
clinical development support services as well as SMO services.
[Contact]
Public Relations Office
EPS Holdings, Inc.
Email: pr@eps.co.jp